This educational activity is designed to highlight current issues in the management of patients with peritoneal surface malignancies. Historically, malignant peritoneal mesothelioma (MPM) has been considered an aggressive and lethal neoplasm. However, contemporary series have demonstrated improved outcomes following a combination of cytoreductive surgery and intraperitoneal chemotherapy. There is evidence that suggests patient survival would improve with surgical therapy.

For example, peritoneal dissemination in colorectal cancer patients represents stage IV disease, and therefore it is usually treated with a combination of cytotoxic chemotherapy and biological agents. Currently there is growing evidence to show that just as there is a subset of patients with stage IV disease with liver metastases who have a long-term benefit from the surgical eradication of their metastatic disease, there is a subset of patients with peritoneal dissemination from colon cancer that may benefit from a complete cytoreduction and HIPEC.  

ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
AMA Credit Designation Statement: 
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of  Participation for Allied Health Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.